Ezh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation

Inflammasome contributes to the pathogenesis of various inflammatory diseases, but the epigenetic mechanism controlling its
activation remains elusive. Here, we found that the histone methyltransferase Ezh2 mediates the activation of multiple types of
inflammasomes in macrophages/microglia independent of its methyltransferase activity and thus promotes inflammasome-related
pathologies. Mechanistically, Ezh2 functions through its SANT2 domain to maintain the enrichment of H3K27 acetylation in the
promoter region of the long noncoding RNA (lncRNA) Neat1, thereby promoting chromatin accessibility and facilitating p65-
mediated transcription of Neat1, which is a critical mediator of inflammasome assembly and activation. In addition, the tumour
suppressor protein p53 competes with Ezh2 for the same binding region in the Neat1 promoter and thus antagonises Ezh2-induced
Neat1 transcription and inflammasome activation. Therefore, loss of Ezh2 strongly promotes the binding of p53, which recruits the
deacetylase SIRT1 for H3K27 deacetylation of the Neat1 promoter and thus suppresses Neat1 transcription and inflammasome
activation. Overall, our study demonstrates an epigenetic mechanism involved in modulating inflammasome activation through an
Ezh2/p53 competition model and highlights a novel function of Ezh2 in maintaining H3K27 acetylation to support lncRNA Neat1
transcription.